Navigation Links
Catalyst Pharmaceutical Partners Reports Second Quarter 2009 Financial Results
Date:8/7/2009

CORAL GABLES, Fla., Aug. 7 /PRNewswire-FirstCall/ -- Catalyst Pharmaceutical Partners, Inc. (Nasdaq: CPRX) today reported financial results for the second quarter and six months ended June 30, 2009.

Second Quarter 2009 Results

For the quarter ended June 30, 2009, the Company reported a net loss of $1,761,887, or $0.13 per basic and diluted share, compared to a net loss of $2,377,440, or $0.19 per basic and diluted share for the same period in 2008. Second quarter 2009 results included non-cash charges relating to stock-based compensation in the amount of $64,532, compared to $123,208 in the same period in 2008. For the six months ended June 30, 2009, the Company reported a net loss of $4,793,088, or $0.34 loss per basic and diluted share, compared to a net loss of $3,961,487, or $0.32 loss per basic and diluted share, for the same period in 2008. Results for the first six months of 2009 included non-cash charges relating to stock-based compensation in the amount of $206,806, compared to $386,612 in the same period in 2008.

Research and development expenses for the second quarter of 2009 were $1,376,253 compared to $1,902,144 in the second quarter of 2008, including non-cash stock-based compensation of $48,440 and $99,532, respectively. Research and development expenses for the six months ended June 30, 2009 were $3,698,885 compared to $2,986,503 for the first six months of 2008, including non-cash stock-based compensation of $120,140 and $274,088, respectively.

General and administrative expenses for the second quarter of 2009 totaled $392,559 compared to $561,533 for the second quarter of 2008, including non-cash stock-based compensation of $16,092 and $23,676, respectively. General and administrative expenses for the first six months of 2009 totaled
'/>"/>

SOURCE Catalyst Pharmaceutical Partners, Inc.
Copyright©2009 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2 3 4 5 6 7

Related biology technology :

1. Using catalysts to stamp nanopatterns without ink
2. Experiments reveal unexpected activity of fuel cell catalysts
3. UCT Specialties (Formerly Petrarch) Announces the Release of Their New Product Guides for Silanes, Silicones, Platinum Catalyst and Glass Coatings
4. IDEXX Laboratories Announces First Customer Deliveries of Catalyst Dx(TM) Chemistry Analyzer and SNAPshot Dx(TM) Analyzer
5. Catalyst Pharmaceutical Partners, Inc. Files Form S-3 Shelf Registration Statement
6. Controlling the size of nanoclusters: First step in making new catalysts
7. Catalyst Pharmaceutical Partners Reports Second Quarter 2008 Financial Results
8. NIST and partners identify tiny gold clusters as top-notch catalysts
9. Catalyst Pharmaceutical Partners, Inc. Announces a $4.5 Million Registered Direct Common Stock Offering
10. Catalyst Pharmaceutical Partners to Present at the Rodman & Renshaw 10th Annual Global Investment Conference
11. PointCross Releases Catalyst for Building Business-Ready SharePoint Solutions in 1/10th the Time

Post Your Comments:
*Name:
*Comment:
*Email:
(Date:11/18/2009)...fast are developing new sensors to detect chemical...ight against the threat of terrorist attacks. , ...n individual or crime scene to gather a sample whi...can detect the presence of chemicals within second...made in response to terrorist threats. , The sc...
(Date:11/18/2009)...Newswire-FirstCall/ -- Masimo (Nasdaq: MASI ), ...Through Motion and Low-Perfusion pulse oximetry, a...ne of the largest healthcare Group Purchasing Orga... purchasing agreement for "gold standard" Masimo S...preferred contract pricing to Uni.H.A.,s 53 member...
(Date:11/18/2009)...Newswire-FirstCall/ - YM BioSciences Inc. (NYSE Am...opment company that identifies and advances a dive... at various stages of development, announced that ...resented today in a poster at the 2009 AACR-NCI-EO...erence in Boston, Massachusetts. The reported resu...
(Date:11/18/2009)...es key cardiac enzymes at multiple time points aft...rt Association 2009 Scientific Sessions , LON... Inc., a biotechnology company pioneering the deve...derived from pathogens, today reported results fro...rp-1), an anti-inflammatory protein derived from t...
Breaking Biology Technology:New technology detects chemical weapons in seconds 2Uni.H.A. in France Signs Purchasing Agreement for Masimo SET(R) Pulse Oximetry Products 2Uni.H.A. in France Signs Purchasing Agreement for Masimo SET(R) Pulse Oximetry Products 3Uni.H.A. in France Signs Purchasing Agreement for Masimo SET(R) Pulse Oximetry Products 4YM BIOSCIENCES ANNOUNCES NIMOTUZUMAB RESULTS IN ADVANCED TRIPLE-NEGATIVE BREAST CANCER MODEL PRESENTED AT AACR-NCI-EORTC MEETING 2YM BIOSCIENCES ANNOUNCES NIMOTUZUMAB RESULTS IN ADVANCED TRIPLE-NEGATIVE BREAST CANCER MODEL PRESENTED AT AACR-NCI-EORTC MEETING 3Viron reports positive Phase II data in Acute Coronary Syndromes (ACS) patients 2Viron reports positive Phase II data in Acute Coronary Syndromes (ACS) patients 3Viron reports positive Phase II data in Acute Coronary Syndromes (ACS) patients 4
...lif., Oct. 2 MannKind Corporation,(Nasdaq: MNKD ...al of,27,014,686 shares of its common stock in reg...incipal stockholder, Chief Executive Officer and,C...ps of investors,including accounts managed by Legg...res, 15,940,489 shares were sold to Mr. Mann at a ...
...ct. 2 Ceregene, Inc., announced today that,it has...ice president and,chief medical officer. Dr. Siffe...grams in Parkinson,s and Alzheimer,s diseases and ...s senior vice president of clinical,and preclinica... wealth of experience in clinical development to C...
...ker Hall of Fame Coach Jim Calhoun Credits Early ...2 Day two of AdvaMed 2007:,The MedTech Conference...nd,benefit from advancements in medical technology... of the economic impact of the medical technology,..., Co-writing "A PASSION TO LEAD: Seven Leadership...
Other Biology Technology:MannKind Corporation Raises $250 Million in Self Managed Registered Direct Offerings of Common Stock 2MannKind Corporation Raises $250 Million in Self Managed Registered Direct Offerings of Common Stock 3Ceregene Appoints Joao Siffert, M.D. to the Position of Chief Medical Officer 2Ceregene Appoints Joao Siffert, M.D. to the Position of Chief Medical Officer 3U.S. Commerce Secretary Gutierrez to Address AdvaMed 2007 2U.S. Commerce Secretary Gutierrez to Address AdvaMed 2007 3
(Date:11/19/2009)...ientists have helped identify and group the genes ...t in maize, an effort that expands their ability t... for biofuels production. , The Purdue scientist...ell biology, published their findings on the 750 c...n Thursday (Nov. 19). They also were co-authors on...
(Date:11/19/2009)...by scientists at The Scripps Research Institute ha...ne long associated with metabolism and metabolic d.... While much research has been conducted on insuli...rst time the hormone has been connected to the fun...e paper was published recently in an advance, onli...
(Date:11/19/2009)...ofessor in the Fischell Department of Bioengineeri...ence Research and Technology Review Day with a tis...and other types of tissue for implantation. , Fi...nted in an eight minute pitch by faculty members a..., held November 12 at the University of Maryland. ...
Breaking Biology News(10 mins):Maize cell wall genes identified, giving boost to biofuel research 2Scripps research scientists find new link between insulin and core body temperature 2Scripps research scientists find new link between insulin and core body temperature 3Scripps research scientists find new link between insulin and core body temperature 4Bioreactor for bone tissue engineering wins professor venture fair 2Bioreactor for bone tissue engineering wins professor venture fair 3Pharmasset Nominates PSI 938 as a New Nucleotide Analog Inhibitor of Hepatitis C for Preclinical Development 50864 1Pharmasset Nominates PSI 938 as a New Nucleotide Analog Inhibitor of Hepatitis C for Preclinical Development 50864 2Pharmasset Nominates PSI 938 as a New Nucleotide Analog Inhibitor of Hepatitis C for Preclinical Development 50864 3Urgent 28R 29 PC and Macroplastique 28R 29 Featured in Numerous IUGA 2009 Sessions 50859 1Urgent 28R 29 PC and Macroplastique 28R 29 Featured in Numerous IUGA 2009 Sessions 50859 2Urgent 28R 29 PC and Macroplastique 28R 29 Featured in Numerous IUGA 2009 Sessions 50859 3Urgent 28R 29 PC and Macroplastique 28R 29 Featured in Numerous IUGA 2009 Sessions 50859 4Cord Blood America Secured 247 5 Million Investment For Series A Preferred Stock 12906 1Cord Blood America Secured 247 5 Million Investment For Series A Preferred Stock 12906 2Cord Blood America Secured 247 5 Million Investment For Series A Preferred Stock 12906 3
...t CFO, to remain through reporting of 2007 fiscal ...q:,AWRE), a leading supplier of broadband technolo...chard Moberg will resume the position of Chief,Fin...erg was previously,Aware,s CFO from June 1996 unti...CFO, will be departing in February after,Aware has...
...MIT scientists have found a way to induce cells to... day serve as tiny engineered blood vessels. , Th...s, development by growing them on a surface with n...ed this month in an online issue of Advanced Mater...e transplanted into tissues such as the kidneys, l...
... U.S. Courts have decreed that the federal gover...ear wastes that will ensure the safety of the publ... that is 200 times the length of recorded history....Long-Term Planning Nuclear Waste Management, a Ca...nt, industry, academia and the environmental commu...
Other Biology News:Aware, Inc. Announces Richard Moberg to Return as CFO 2Aware, Inc. Announces Richard Moberg to Return as CFO 3MIT works toward engineered blood vessels 2Managing nuclear wastes for the millennia 2
...O384R are fast multi-channel pipetting platforms c...ferent sizes, with a multi-channel head and a robo... saving, with true parallel processing of sample p...eedom EVOware program. Each of these robotic sol...
SigmaScreen APS Coated Slides for Microarrays from Sigma-Aldrich
Bovine Serum, Adult from Sigma-Aldrich
...(CYP450) metabolite postulated to play an autacoid...t cerebral microvessels, 20-HETE is a vasoconstric...vasoconstriction. 20-HETE is excreted mainly as th... 20-HETE (20-40 pg/ml in human urine) is about 10-...
Biology Products: